Aptose Biosciences Inc. will hold a rescheduled special meeting of shareholders in January 2026 to vote on proposals including the continuance of Aptose from the Canada Business Corporations Act to the Business Corporations Act (Alberta) and the subsequent acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., through a statutory plan of arrangement. The board of directors unanimously recommends that shareholders vote FOR the special resolutions approving the continuance and the arrangement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptose Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9605419-en) on December 19, 2025, and is solely responsible for the information contained therein.
Comments